Table 1 Baseline characteristics for each type of anticoagulation
| Â | VKA (n = 1021) | DOAC (n = 426) | Total (n = 1447) | p |
|---|---|---|---|---|
Demographic characteristic | ||||
 Sex, male, [n (%)] | 508 (49.8) | 217 (50.9) | 725 (50.1) | 0.681 |
 Age (years), med (IQR) | 80 (74–85) | 80 (74–85) | 80 (74–85) | 0.240 |
Comorbidities | ||||
 HAS-BLED Score, [med (iqr)] | 3 (2–3) | 3 (2–3) | 3 (2–3) | 0.083 |
 Charlson Comorbidity Index, [med (iqr)] | 6 (4–8) | 6 (5–8) | 6 (4–8) | 0.015 |
 No. of drugs, [med (iqr)] | 7 (4–10) | 8 (5–10) | 7 (5–10) | 0.008 |
 No. of diagnoses, [med (iqr)] | 5 (4–6) | 5 (4–6) | 5 (4–6) | 0.004 |
 Hypertension, [n (%)] | 744 (72.9) | 325 (76.3) | 1069 (73.9) | 0.177 |
 Diabetes, [n (%)] | 229 (22.4) | 99 (23.2) | 328 (22.7) | 0.737 |
 CHF, [n (%)] | 225 (22.0) | 103 (24.2) | 328 (22.7) | 0.375 |
 Coronary artery disease, [n (%)] | 97 (9.5) | 43 (10.1) | 140 (9.7) | 0.728 |
 Cerebrovascular disease,[n (%)] | 228 (22.3) | 131 (30.8) | 359 (24.8) | 0.001 |
 Hemiplegia, [n (%)] | 115 (11.3) | 50 (11.7) | 165 (11.4) | 0.796 |
 Renal insufficiency, [n (%)] | 401 (39.3) | 145 (34.0) | 546 (37.7) | 0.061 |
 PAVD, [n (%)] | 117 (11.5) | 27 (6.3) | 144 (10.0) | 0.003 |
 Liver disease, [n (%)] | 17 (1.7) | 13 (3.1) | 30 (2.1) | 0.092 |
 COPD, [n (%)] | 98 (9.6) | 53 (12.4) | 151 (10.4) | 0.107 |
 Malignancy, [n (%)] | 104 (10.2) | 59 (13.8) | 163 (11.3) | 0.045 |
 Dementia, [n (%)] | 106 (10.4) | 73 (17.1) | 179 (12.4) | < 0.001 |
 Alcoholism, [n (%)] | 8 (0.8) | 14 (3.3) | 22 (1.5) | < 0.001 |
 Connective tissue disease, [n (%)] | 36 (3.5) | 14 (3.3) | 50 (3.5) | 0.820 |
 Peptic ulcer disease, [n (%)] | 174 (17.0) | 94 (22.1) | 268 (18.5) | 0.025 |
 AIDS, [n (%)] | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
 History of bleeding, [n (%)] | 177 (17.3) | 78 (18.3) | 255 (17.6) | 0.658 |